WhiteBook2_Part2 - 20
Results
European Commission funding for digestive disease research (Horizon 2020)
In total, 166 Horizon 2020 funded digestive disease related research projects were identified,
with combined European Commission funding of €352,777,536 (see Appendix for list of
projects). A small number of identified projects (n=6) were assigned to more than one
disease field (excluding sub-categorisation). Stated start dates amongst the projects ranged
from the years 2015 to 2022.
Figure 14 and Table 1 show European Commission funding in Euros for digestive disease
related Horizon 2020 projects summed by disease. Inflammatory bowel disease received a
large amount of research funding at over €150 million. Chronic liver disease related projects
that were not assigned to a particular disease sub-category were granted around €86 million
in total. Additionally, non-alcoholic fatty liver disease, chronic hepatitis B, and coeliac disease
each received over €20 million. Most of the digestive diseases analysed, however, received
relatively small amounts of research funding. Irritable bowel syndrome received €1.7 million,
and three digestive diseases, including gastroesophageal reflux disease, received €50,000
each. Five diseases did not receive any funding, including dyspepsia and paralytic ileus and
intestinal obstruction. Whilst there were no identified projects specifically related to peptic
ulcer disease or gastritis and duodenitis, nearly €375,000 was awarded to Helicobacter pylori
screening or treatment related projects.
Figure 14.
European Commission funding for Horizon 2020 digestive disease related research projects
150,000,000
100,000,000
50,000,000
Source: authors' compilation using data extracted from CORDIS database.
Funding per project may be assigned to more than one disease .
*Chronic liver diseases (not including disease sub−categor ies: Alcohol−related liver disease; Chronic hepatitis B; Chronic hepatitis C;
Non−alcoholic fatty liver disease).
White Book 2: Part 2
17
Inflammatory bowel disease
Chronic liver diseases*
Non−alcoholic fatty liver disease
Chronic hepatitis B
Coeliac disease
Alcohol−related liver disease
Chronic hepatitis C
Pancreatitis
Gallbladder and biliary diseases
Irritable bowel syndrome
Eosinophilic oesophagitis
Gastroesophageal reflux disease
Inguinal, femoral, and abdominal hernia
Appendicitis
Dyspepsia
Gastritis and duodenitis
Paralytic ileus and intestinal obstruction
Peptic ulcer disease
Euros
WhiteBook2_Part2
Table of Contents for the Digital Edition of WhiteBook2_Part2
WhiteBook2_Part2 - 1
WhiteBook2_Part2 - 2
WhiteBook2_Part2 - 3
WhiteBook2_Part2 - 4
WhiteBook2_Part2 - 5
WhiteBook2_Part2 - 6
WhiteBook2_Part2 - 7
WhiteBook2_Part2 - 8
WhiteBook2_Part2 - 9
WhiteBook2_Part2 - 10
WhiteBook2_Part2 - 11
WhiteBook2_Part2 - 12
WhiteBook2_Part2 - 13
WhiteBook2_Part2 - 14
WhiteBook2_Part2 - 15
WhiteBook2_Part2 - 16
WhiteBook2_Part2 - 17
WhiteBook2_Part2 - 18
WhiteBook2_Part2 - 19
WhiteBook2_Part2 - 20
WhiteBook2_Part2 - 21
WhiteBook2_Part2 - 22
WhiteBook2_Part2 - 23
WhiteBook2_Part2 - 24
WhiteBook2_Part2 - 25
WhiteBook2_Part2 - 26
WhiteBook2_Part2 - 27
WhiteBook2_Part2 - 28
WhiteBook2_Part2 - 29
WhiteBook2_Part2 - 30
WhiteBook2_Part2 - 31
WhiteBook2_Part2 - 32
WhiteBook2_Part2 - 33
WhiteBook2_Part2 - 34
WhiteBook2_Part2 - 35
WhiteBook2_Part2 - 36
WhiteBook2_Part2 - 37
WhiteBook2_Part2 - 38
WhiteBook2_Part2 - 39
WhiteBook2_Part2 - 40
WhiteBook2_Part2 - 41
WhiteBook2_Part2 - 42
WhiteBook2_Part2 - 43
WhiteBook2_Part2 - 44
WhiteBook2_Part2 - 45
WhiteBook2_Part2 - 46
WhiteBook2_Part2 - 47
WhiteBook2_Part2 - 48
WhiteBook2_Part2 - 49
WhiteBook2_Part2 - 50
WhiteBook2_Part2 - 51
WhiteBook2_Part2 - 52
WhiteBook2_Part2 - 53
WhiteBook2_Part2 - 54
WhiteBook2_Part2 - 55
WhiteBook2_Part2 - 56
https://www.nxtbookmedia.com